Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B

The novel anticancer drug ABT-737 is a Bcl-2 Homology 3 (BH3)-mimetic that induces apoptosis by inhibiting pro-survival Bcl-2 proteins. ABT-737 binds with equal affinity to Bcl-2, Bcl-xL and Bcl-w in vitro and is expected to overrule apoptosis resistance mediated by these Bcl-2 proteins in equal mea...

Descripción completa

Detalles Bibliográficos
Autores principales: Rooswinkel, R W, van de Kooij, B, Verheij, M, Borst, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434657/
https://www.ncbi.nlm.nih.gov/pubmed/22875003
http://dx.doi.org/10.1038/cddis.2012.109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434657/
https://www.ncbi.nlm.nih.gov/pubmed/22875003
http://dx.doi.org/10.1038/cddis.2012.109

Ejemplares similares